196 related articles for article (PubMed ID: 37955690)
1. Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer.
Mitra S; Biswas P; Bandyopadhyay A; Gadekar VS; Gopalakrishnan AV; Kumar M; Radha ; Nandy S
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2637-2650. PubMed ID: 37955690
[TBL] [Abstract][Full Text] [Related]
2. Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-κB and lncRNAs.
Awasthee N; Shekher A; Rai V; Verma SS; Mishra S; Dhasmana A; Gupta SC
Apoptosis; 2022 Apr; 27(3-4):261-282. PubMed ID: 35122181
[TBL] [Abstract][Full Text] [Related]
3. Piperlongumine (piplartine) as a lead compound for anticancer agents - Synthesis and properties of analogues: A mini-review.
Piska K; Gunia-Krzyżak A; Koczurkiewicz P; Wójcik-Pszczoła K; Pękala E
Eur J Med Chem; 2018 Aug; 156():13-20. PubMed ID: 30006159
[TBL] [Abstract][Full Text] [Related]
4. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer.
Kumar S; Agnihotri N
Biomed Pharmacother; 2019 Jan; 109():1462-1477. PubMed ID: 30551398
[TBL] [Abstract][Full Text] [Related]
5. Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.
Han SS; Han S; Kamberos NL
Biochem Biophys Res Commun; 2014 Sep; 452(3):669-75. PubMed ID: 25193702
[TBL] [Abstract][Full Text] [Related]
6. Overview of piperlongumine analogues and their therapeutic potential.
Zhu P; Qian J; Xu Z; Meng C; Zhu W; Ran F; Zhang W; Zhang Y; Ling Y
Eur J Med Chem; 2021 Aug; 220():113471. PubMed ID: 33930801
[TBL] [Abstract][Full Text] [Related]
7. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway.
Thongsom S; Suginta W; Lee KJ; Choe H; Talabnin C
Apoptosis; 2017 Nov; 22(11):1473-1484. PubMed ID: 28913568
[TBL] [Abstract][Full Text] [Related]
8. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
Zhang P; Shi L; Zhang T; Hong L; He W; Cao P; Shen X; Zheng P; Xia Y; Zou P
Cell Oncol (Dordr); 2019 Dec; 42(6):847-860. PubMed ID: 31493144
[TBL] [Abstract][Full Text] [Related]
9. Piperine for treating breast cancer: A review of molecular mechanisms, combination with anticancer drugs, and nanosystems.
Quijia CR; Chorilli M
Phytother Res; 2022 Jan; 36(1):147-163. PubMed ID: 34559416
[TBL] [Abstract][Full Text] [Related]
10. Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line.
Seber S; Sirin DY; Yetisyigit T; Bilgen T
Niger J Clin Pract; 2020 Mar; 23(3):386-391. PubMed ID: 32134040
[TBL] [Abstract][Full Text] [Related]
11. Piperlongumine induces autophagy in biliary cancer cells via reactive oxygen species-activated Erk signaling pathway.
Chen SY; Huang HY; Lin HP; Fang CY
Int J Mol Med; 2019 Nov; 44(5):1687-1696. PubMed ID: 31485612
[TBL] [Abstract][Full Text] [Related]
12. Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells.
Rawat L; Hegde H; Hoti SL; Nayak V
Biomed Pharmacother; 2020 Aug; 128():110243. PubMed ID: 32470748
[TBL] [Abstract][Full Text] [Related]
13. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.
Bharadwaj U; Eckols TK; Kolosov M; Kasembeli MM; Adam A; Torres D; Zhang X; Dobrolecki LE; Wei W; Lewis MT; Dave B; Chang JC; Landis MD; Creighton CJ; Mancini MA; Tweardy DJ
Oncogene; 2015 Mar; 34(11):1341-53. PubMed ID: 24681959
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
Piska K; Koczurkiewicz P; Wnuk D; Karnas E; Bucki A; Wójcik-Pszczoła K; Jamrozik M; Michalik M; Kołaczkowski M; Pękala E
Chem Biol Interact; 2019 Feb; 300():40-48. PubMed ID: 30611789
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cisplatin resistance in oral squamous cell carcinoma by piperlongumine loaded smart nanoparticles through inhibition of Hippo-YAP signaling pathway.
Sa P; Singh P; Panda S; Swain RK; Dash R; Sahoo SK
Transl Res; 2024 Jun; 268():63-78. PubMed ID: 38499286
[TBL] [Abstract][Full Text] [Related]
16. Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells.
Park JA; Na HH; Jin HO; Kim KC
Mol Cells; 2019 Dec; 42(12):884-892. PubMed ID: 31735020
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization.
Liu D; Qiu XY; Wu X; Hu DX; Li CY; Yu SB; Pan F; Chen XQ
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):165-172. PubMed ID: 29037814
[TBL] [Abstract][Full Text] [Related]
18. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo.
Duan C; Zhang B; Deng C; Cao Y; Zhou F; Wu L; Chen M; Shen S; Xu G; Zhang S; Duan G; Yan H; Zou X
Tumour Biol; 2016 Aug; 37(8):10793-804. PubMed ID: 26874726
[TBL] [Abstract][Full Text] [Related]
19. Piper nigrum ethanolic extract rich in piperamides causes ROS overproduction, oxidative damage in DNA leading to cell cycle arrest and apoptosis in cancer cells.
de Souza Grinevicius VM; Kviecinski MR; Santos Mota NS; Ourique F; Porfirio Will Castro LS; Andreguetti RR; Gomes Correia JF; Filho DW; Pich CT; Pedrosa RC
J Ethnopharmacol; 2016 Aug; 189():139-47. PubMed ID: 27178634
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells.
Gong LH; Chen XX; Wang H; Jiang QW; Pan SS; Qiu JG; Mei XL; Xue YQ; Qin WM; Zheng FY; Shi Z; Yan XJ
Oxid Med Cell Longev; 2014; 2014():906804. PubMed ID: 24895529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
